Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 6/20 | 0.34 |
| ▸ | GAB1 | Q13480 | 4/20 | 0.34 |
| ▸ | IRS1 | P35568 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP3 | P08254 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 3/20 | 0.32 |
| ▸ | MMP14 | P50281 | 3/20 | 0.32 |
| ▸ | MMP25 | Q9NPA2 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684588 | 0.91 | HTT (0.33) | — | |
| SCHEMBL3689889 | 0.90 | ALDH1A1 (0.34) | MMP2MMP9MMP1MMP3MMP8 | |
| SCHEMBL3691243 | 0.87 | FAAH (0.40) | FAAHAKT1GAB1IRS1 | |
| SCHEMBL3679728 | 0.86 | MMP9 (0.53) | MMP2MMP9MMP1MMP3MMP8 | |
| SCHEMBL3690902 | 0.86 | FAAH (0.41) | FAAHAKT1GAB1IRS1 | |
| Trifluoroacetic Acid SCHEMBL3682804 | 0.86 | MMP2 (0.40) | MMP2MMP9FAAHAKT1GAB1 | |
| Trifluoroacetic Acid SCHEMBL3682809 | 0.86 | MMP2 (0.40) | MMP2MMP9FAAHAKT1GAB1 | |
| SCHEMBL13410002 | 0.85 | S1PR1 (0.42) | MMP2MMP9AKT1GAB1IRS1 | |
| SCHEMBL3679526 | 0.84 | ALDH1A1 (0.34) | — | |
| SCHEMBL3683184 | 0.83 | FAAH (0.35) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | MMP2 961/4885MMP9 1084/4885FAAH 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.